World Journal of
Pharmaceutical and Life Sciences

COMPARATIVE STUDY OF SAROGLITAZAR AND PIOGLITAZONE ON HIGH FAT DIET-LOW DOSE STREPTOZOTOCIN INDUCED TYPE-2 DIABETES IN WISTER RATS

S. Viswanth Reddy*, G. Avinash and R. Sagar

ABSTRACT

Hyperlipidemia is the major predisposing risk factor for occurrence of type-2 diabetes. The present study was planned to investigate the hypoglycaemic and lipid lowering comparative activity study of Saroglitazar (PPAR?/? agonist) and Pioglitazone (PPAR? agonist) in HFD- low dose Sreptozotocin induced type-2 diabetes in male Waster rats. Diabetes was induced by single i.p injection of low dose of Streptozotocin (40 mg/kg bd.wt) followed by 21 days of high fat diet (HFD) feeding in 6-8 week old male Wister rats. Body weight gain, blood glucose and lipid parameters were measured. Oral treatment of a PPAR?/? dual agonist Saroglitazar (4 mg/kg) and PPAR? agonist Pioglitazone (10 mg/kg) were significantly reduced the mean body weight, blood glucose, and plasma total cholesterol, triglycerides levels. Sarogliatazar and Pioglitazone showed no significant effect on LDL-C and HDL-C levels. Sarogliatazar showed better activity when compared with Pioglitazone, because of the dual agonistic action of Saroglitazar on PPAR?/? Receptors, it favours the concomitant reduction of blood glucose (PPAR? action) and lipid (PPAR?/? action) levels. Over all the results showed that Saroglitazar a PPAR?/? dual agonist, a drug approved in India for treatment of diabetic dyslipidemia shows significant reduction in body weight, blood glucose and lipid parameters when compared to PPAR? agonist (Pioglitazone) in high fat diet with chemical induced model of type-2 diabetes mellitus. Suggesting it’s as first line drug for treatment of diabetic dyslipidemia.

[Full Text Article]   [Download Certificate]